Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 13/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584631 | 0.88 | ADRB1 (0.54) | ADRB3ADRB1EPHX2GAAADRB2 | |
| SCHEMBL4584636 | 0.88 | ADRB1 (0.54) | ADRB3ADRB1EPHX2GAAADRB2 | |
| SCHEMBL27935185 | 0.84 | BCAT2 (0.58) | — | |
| SCHEMBL28038749 | 0.84 | BCAT2 (0.58) | — | |
| SCHEMBL8560298 | 0.83 | ALDH1A1 (0.61) | ADRB3ADRB1EPHX2 | |
| SCHEMBL8560709 | 0.83 | ALDH1A1 (0.61) | ADRB3ADRB1EPHX2 | |
| SCHEMBL26177168 | 0.82 | ADRB3 (0.52) | ADRB3ADRB1EPHX2ADRB2CYP3A4 | |
| SCHEMBL7989952 | 0.81 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7989947 | 0.81 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| SCHEMBL26177231 | 0.79 | ADRB3 (0.46) | ADRB3ADRB1EPHX2ADRB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5792871-A | BETA-3 AGONIST USEFUL IN TREATMENT OF OBESITY AND DIABETES | MERCK & CO., INC. (US) | 1998-08-11 | — | — | US | disclosed |